Evidence map›Paper›PMID 35783648›Full record

ArticleFrontiers in medicine2022

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a

Maria Molina-Molina, Michael Kreuter, Vincent Cottin, Tamera J Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M Maher

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03099187 (Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03099187 phase2completednot on this map

Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD

TypeinterventionalSponsorHoffmann-La RocheRan2017 to 2020Enrolled253ConditionsLung Diseases, InterstitialArmsPirfenidone, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 7 countries.

Maria Molina-MolinaILD Unit, Respiratory Department, University Hospital of Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Michael KreuterCenter for Interstitial and Rare Lung Diseases, Dep-Pneumonology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Vincent CottinNational Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Member of ERN-LUNG, Lyon, France.
Tamera J CorteDepartment of Respiratory Medicine, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.
Frank GilbergF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Klaus-Uwe KirchgaesslerF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Judit AxmannF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Toby M MaherInterstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom.
Roche (Switzerland) · CHCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESGerman Center for Lung Research · DEInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRRoyal Brompton Hospital · GBThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 12-13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent Phase 2 study (NCT03099187) described a significant effect of pirfenidone vs. placebo on forced vital capacity (FVC) measured by site spirometry in patients with progressive fibrosing uILD (hereafter referred to as the pirfenidone in uILD study). Here, we present the results from a Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03099187.

Indexed as

lung functionpirfenidonepost-hoc analysissurgical lung biopsyunclassifiable interstitial lung disease

Identifiers

PMID35783648
PMCPMC9247211
OpenAlexW4283026460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.